Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC).

Conference call details:

Monday June 17, 2024

8:30 a.m. ET / 5:30 a.m.... (continue reading...)

Online poker platform drop the Father’s Day treats

ST JOHN’S, Antigua--(BUSINESS WIRE)-- Juicy Stakes Casino is bringing you more poker than ever before this June – while dropping the daddy of all offers this week. Read on to find out all about it.

A familiar favourite up first… the world famous Sunday Myriad. The Texas Hold ‘Em tournament that takes place every Sunday, with a $10,000 GTD weekly jackpot. Three fresh formats – Deepstack, Progressive Bounty and... (continue reading...)

The massive dragon caps off the weeklong “House of the Dragon” takeover at the Observatory

NEW YORK--(BUSINESS WIRE)-- A 270-foot-long dragon has landed in the center of New York City – atop the iconic Empire State Building (ESB). In partnership with Max, ESB has acknowledged that Vhagar the Dragon has coiled herself around its mast just as ESB and Max cap off their weeklong “House of the Dragon” takeover.

This press release features multimedia. View the full... (continue reading...)

WASHINGTON--(BUSINESS WIRE)-- BreachBits, Inc. announced a reseller partnership between SentryMark, Inc. and Nippon Telematique, Inc. (NTI) to distribute BreachRisk™ solutions in Japan.

BreachBits delivers attack surface monitoring (ASM) and automated penetration testing solutions that are powered by their BreachRisk Platform. Built by U.S. military cyber warfare veterans, the BreachRisk Platform leverages AI and automation to provide cyber risk assessments from... (continue reading...)

First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and showed a favorable trend in overall... (continue reading...)